News & Media / Newsroom
From Italy, with European, Chinese and Iranian partners, the attempt to answer the questions generated by the SARS-CoV-2 virus: a genetic study at the basis of new diagnostic and therapeutic solutions.
The Fab13 members of Farmindustria joined the fundraiser promoted by Fimmg & Cittadinanzattiva to find and distribute collective protection devices for all primary care physicians.
Innovation Pharmaceuticals announces License Agreement with Alfasigma S.p.A. for the development and commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis.
Alfasigma USA has acquired the brand ZELNORM (tegaserod), a treatment for IBS-C, from Sloan Pharma, with the aim to relaunch the brand in the United States.
The merger between the 3 Italian companies Alfa Wassermann, Sigma-Tau and Biofutura within Alfasigma SpA has been announced last August 1st.
Alfasigma announces the acquisition of Pamlab, a U.S. based company with a leading position in the manufacturing and distribution of medical foods, from Nestlé Health Science.